Amedisys, Inc. (NASDAQ:AMED) Receives $100.75 Average Target Price from Brokerages

Shares of Amedisys, Inc. (NASDAQ:AMEDGet Free Report) have received a consensus rating of “Hold” from the six ratings firms that are currently covering the firm, Marketbeat reports. Five equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $100.75.

Separately, Stephens reaffirmed an “equal weight” rating and set a $101.00 price objective on shares of Amedisys in a research note on Wednesday.

Read Our Latest Stock Analysis on AMED

Amedisys Price Performance

AMED stock opened at $92.60 on Wednesday. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05. Amedisys has a one year low of $82.15 and a one year high of $98.95. The firm has a market capitalization of $3.03 billion, a PE ratio of 36.75, a P/E/G ratio of 1.82 and a beta of 0.73. The firm has a 50-day moving average of $90.11 and a two-hundred day moving average of $93.64.

Institutional Trading of Amedisys

Hedge funds have recently made changes to their positions in the stock. Norges Bank acquired a new position in Amedisys during the fourth quarter valued at approximately $83,061,000. Wealthfront Advisers LLC acquired a new position in Amedisys during the fourth quarter valued at approximately $72,970,000. Pentwater Capital Management LP grew its holdings in Amedisys by 178.3% during the fourth quarter. Pentwater Capital Management LP now owns 1,180,000 shares of the health services provider’s stock valued at $107,132,000 after purchasing an additional 756,000 shares during the last quarter. Pacer Advisors Inc. grew its stake in shares of Amedisys by 11,621.9% in the fourth quarter. Pacer Advisors Inc. now owns 558,197 shares of the health services provider’s stock worth $50,679,000 after acquiring an additional 553,435 shares during the last quarter. Finally, Polar Asset Management Partners Inc. acquired a new stake in shares of Amedisys in the third quarter worth $28,953,000. 94.36% of the stock is owned by hedge funds and other institutional investors.

About Amedisys

(Get Free Report

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Featured Articles

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.